Organon & Co. (BIT:1OGN)
Italy · Delayed Price · Currency is EUR | Market Cap | 2.06B -38.9% |
| Revenue (ttm) | 5.29B -2.9% |
| Net Income | 159.27M -78.4% |
| EPS | 0.61 -78.4% |
| Shares Out | n/a |
| PE Ratio | 12.95 |
| Forward PE | 2.70 |
| Dividend | 0.05 (0.65%) |
| Ex-Dividend Date | Nov 19, 2025 |
| Volume | n/a |
| Average Volume | 332 |
| Open | n/a |
| Previous Close | 7.94 |
| Day's Range | n/a |
| 52-Week Range | 4.86 - 14.30 |
| Beta | n/a |
| RSI | 75.08 |
| Earnings Date | May 7, 2026 |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, whi... [Read more]
Financial Performance
In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.
Financial numbers in USD Financial StatementsNews
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release its first quarter 2026 financial results and host conference call on May 7, 2026.
Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
JERSEY CITY, N.J.--(BUSINESS WIRE)--VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.
Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet
Citing people familiar with the matter, the Economic Times reported that Sun Pharma has completed an extensive due diligence process spanning more than three months.
This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring.
Organon stock jumped after a report said Sun Pharmaceutical Industries is nearing an all-cash deal for the women's health company.
This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works
Organon shares are popping Friday on signs of a takeover deal.
These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More.
Lumentum and Coherent were gaining on signs of strong artificial-intelligence hardware demand, while Organon was boosted by a takeover report.
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS
STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (P...
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has ...
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.
Organon Completes Divestiture of JADA® System to Laborie
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company.
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs.
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.
Organon Analysts Cut Their Forecasts Following Q3 Results
Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.
Organon Reports Results for the Third Quarter Ended September 30, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this ...
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings...
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices
Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplano...